Phase Ib/II study of BCL-2 inhibitor lisaftoclax (APG-2575) safety and tolerability when administered alone or combined with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in patients with estrogen receptor-positive (ER plus ) breast cancer or advanced solid tumors

被引：0
|
作者：
Kalinsky, Kevin
Tolcher, Anthony W.
Wang, Shushen
Meric-Bernstam, Funda
Winkler, Robert
Li, Mingyu
Sun, Xuemei
Pan, Wentao
Paudyal, Bishnuhari
Liang, Zhiyan
Lu, Ming
Yang, Dajun
Zhai, Yifan
机构：
[1] Emory Univ, Winship Canc Inst, Glenn Family Breast Ctr, Dept Hematol & Med Oncol, Atlanta, GA USA
[2] Emory Univ, Winship Canc Inst, Breast Med Oncol, Atlanta, GA USA
[3] NEXT Oncol & Texas Oncol, San Antonio, TX USA
[4] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou, Peoples R China
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[6] Ascentage Pharma Grp Inc, Rockville, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1122
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Effect of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy (≤6 mo or >6 mo) on alpelisib benefit in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve
    Chia, Stephen
    Ciruelos, Eva M.
    Rugo, Hope S.
    Lerebours, Florence
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Prat, Aleix
    Bachelot, Thomas
    Turner, Nicholas
    Gu, Ennan
    Arce, Christina
    Akdere, Murat
    Juric, Dejan
    CANCER RESEARCH, 2022, 82 (04)
  • [32] pionERA Breast Cancer (BC): Phase III study of first-line (1L) giredestrant vs. fulvestrant, both combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), in patients (pts) with estrogen receptor-positive (ER+), HER2-locally advanced/metastatic BC (LA/mBC) with resistance to prior adjuvant (adj) endocrine therapy (ET)
    Kalinsky, Kevin
    Jeselsohn, Rinath
    Bellet, Meritxell
    Fasching, Peter A.
    Gomez-Abuin, Gonzalo
    Jung, Kyung Hae
    Lavalle, Sandrine
    Opez-Valverde, Vanesa L. Prime
    Lu, Yen-Shen
    Schwab, Richard B.
    Turner, Nick
    Breton, Vanessa
    Zambelli, Alberto
    Andre, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Alpelisib plus letrozole in patients with PIK3CA-mutated, hormone-receptor positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results
    Rugo, Hope S.
    Lerebours, Florence
    Juric, Dejan
    Turner, Nicholas
    Chia, Stephen
    Drullinsky, Pamela
    Prat, Aleix
    Villanueva Vazquez, Rafael
    Akdere, Murat
    Arce, Christina
    Shen, Yu-Ming
    Ciruelos, Eva
    CANCER RESEARCH, 2021, 81 (04)
  • [34] CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
    Gao, Jennifer J.
    Cheng, Joyce
    Bloomquist, Erik
    Sanchez, Jacquelyn
    Wedam, Suparna B.
    Singh, Harpreet
    Amiri-Kordestani, Laleh
    Ibrahim, Amna
    Sridhara, Rajeshwari
    Goldberg, Kirsten B.
    Theoret, Marc R.
    Kluetz, Paul G.
    Blumenthal, Gideon M.
    Pazdur, Richard
    Beaver, Julia A.
    Prowell, Tatiana M.
    LANCET ONCOLOGY, 2020, 21 (02): : 250 - 260
  • [35] A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer (HR plus MBC) and metastatic ovarian cancer (MOC)
    Herold, Christina I.
    Trippa, Lorenzo
    Li, Tianyu
    Khanh Do
    Bardia, Aditya
    Anderson, Leilani
    Montazeri, Kamaneh
    Pittenger, Jessica
    Andrews, Chelsea
    Mittendorf, Elizabeth A.
    Goel, Shorn
    Winer, Eric P.
    Shapiro, Geoffrey I.
    Tolaney, Sara M.
    CANCER RESEARCH, 2020, 80 (04)
  • [36] BYLieve: A phase II study of alpelisib (ALP) with fulvestrant (FUL) or letrozole (LET) for treatment of PIK3CA mutant, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy.
    Rugo, Hope S.
    Bianchi, Giulia Valeria
    Chia, Stephen K. L.
    Turner, Nicholas C.
    Juric, Dejan
    Jacot, William
    Borrego, Manuel Ruiz
    Chap, Linnea I.
    Brown-Glaberman, Ursa Abigail
    Nienstedt, Carolyn C.
    Sophos, Nikos
    Ridolfi, Antonia
    Lin, Chinjune
    Ciruelos, Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [37] Alpelisib plus fulvestrant in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A
    Ciruelos, Eva M.
    Lerebours, Florence
    Rugo, Hope S.
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Prat, Aleix
    Bachelot, Thomas
    Neven, Patrick
    Park, Yeon Hee
    Turner, Nicholas
    Juric, Dejan
    Gu, Ennan
    Arce, Christina H.
    Akdere, Murat
    Chia, Stephen
    CANCER RESEARCH, 2022, 82 (04)
  • [38] A phase Ib trial of fulvestrant+CDK4/6 inhibitor (CDK4/6i) palbociclib plus pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib in FGFR-amplified/ER+/HER2-negative metastatic breast cancer (MBC)
    Mayer, Ingrid A.
    Haley, Barbara B.
    Abramson, Vandana G.
    Brufsky, Adam
    Rexer, Brent
    Stringer-Reasor, Erica
    Jhaveri, Komal L.
    Sanders, Melinda
    Ericsson-Gonzalez, Paula I.
    Ye, Fei
    Arteaga, Carlos L.
    CANCER RESEARCH, 2021, 81 (04)
  • [39] Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve.
    Chia, Stephen K. L.
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Juric, Dejan
    Bachelot, Thomas
    Rugo, Hope S.
    Ciruelos, Eva M.
    Lerebours, Florence
    Prat, Aleix
    Akdere, Murat
    Arce, Christina
    Gu, Ennan
    Turner, Nicholas C.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, in patients with metastatic AR plus /ER plus breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a phase II clinical study
    Palmieri, C.
    Linden, H.
    Birrell, S.
    Lim, E.
    Schwartzberg, L. S.
    Rugo, H. S.
    Cobb, P.
    Jain, K.
    Vogel, C.
    O'Shaughnessy, J.
    Johnston, S. R. D.
    Getzenberg, R. H.
    Barnette, K. G.
    Steiner, M.
    Brufsky, A. M.
    Overmoyer, B.
    ANNALS OF ONCOLOGY, 2021, 32 : S66 - S66
12345